Recombinant Human NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 8, mitochondrial (NDUFB8)

Basic Research Questions

What experimental strategies validate NDUFB8's role in mitochondrial Complex I stability?

• Methodological approach:

  • Use siRNA knockdown in cell lines (e.g., HEK293) to assess Complex I assembly via Blue Native PAGE .

  • Measure oxygen consumption rates (OCR) before/after knockdown using Seahorse XF Analyzers .

  • Validate rescue experiments by reintroducing recombinant NDUFB8 via lentiviral transduction .

How do researchers distinguish NDUFB8-specific dysfunction from broader Complex I defects?

• Key techniques:

  • Perform quadruple immunofluorescent assays to quantify NDUFB8 abundance relative to other subunits (e.g., COX-I) in muscle fibers .

  • Compare enzymatic activity of isolated Complex I (NADH:ubiquinone oxidoreductase assay) in samples with/without NDUFB8 mutations .

  • Analyze mitochondrial supercomplex formation via 2D-BN-PAGE .

What quality control measures ensure recombinant NDUFB8 functionality?

• Validation workflow:

  • Confirm purity (>90%) via 12.5% SDS-PAGE with Coomassie Blue staining .

  • Test antigenicity using antibody competition assays (e.g., Novus Biologicals NBP3-17898PEP) .

  • Verify structural integrity via circular dichroism (CD) spectroscopy .

Advanced Research Challenges

How to resolve contradictions in NDUFB8 solubility across expression systems?

What methodologies identify NDUFB8 nitration in oxidative stress models?

• Step-by-step protocol:

  • Treat endothelial cells with peroxynitrite (ONOO⁻) to induce nitration .

  • Immunoprecipitate NDUFB8 using anti-nitrotyrosine antibodies.

  • Confirm nitration sites via LC-MS/MS (e.g., Tyr-76 and Tyr-128) .

  • Correlate findings with mitochondrial membrane potential (ΔΨm) using TMRE staining .

How to reconcile conflicting biochemical data on NDUFB8’s catalytic role?

• Critical analysis framework:

  • Compare accessory subunit vs. structural subunit hypotheses using:

    • Cryo-EM structures (e.g., PDB 5XTD) to map NDUFB8’s position in Complex I .

    • Kinetic assays with/without recombinant NDUFB8 supplementation .

  • Prioritize studies showing >60% Complex I activity loss in NDUFB8-deficient fibroblasts .

Translational Research Considerations

What in vivo models best recapitulate NDUFB8-linked Leigh syndrome phenotypes?

• Model comparison:

  Model	Advantages	Limitations
  Ndufb8 KO mice	Progressive encephalopathy, lactic acidosis	High perinatal mortality
  Zebrafish morphants	Rapid screening of cardiac defects	Limited CNS pathology resolution
  Patient-derived iPSCs	Human mutation context	Variable differentiation efficiency

How to optimize NDUFB8-targeted antibody validation for immunohistochemistry?

• Validation checklist:

  • Test cross-reactivity against other Complex I subunits (e.g., NDUFS3) via Western blot .

  • Use tissues from NDUFB8 mutation carriers as negative controls .

  • Quantify signal linearity across dilution series (R² >0.95 required) .

What bioinformatics pipelines prioritize NDUFB8 variants for functional testing?

• Variant prioritization criteria:

  • CADD score >20 .

  • Conservation across 100 vertebrate species (PhyloP >1.5) .

  • Structural proximity to ubiquinone-binding sites (≤5Å) .

  • Co-segregation in pedigrees with Leigh syndrome .